Century Therapeutics, Inc. Common Stock (IPSC) Stock Price

IPSCStock

$2.17+291.72%52W

Market Cap$392.93M

P/E—

PEG Ratio—

Div yield—

Beta1.64

IPSC Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-10.29%

Price vs S&P 500 (4W)0.36%

VGM Score77.92

Book Value / Share (Quarterly)$1.47

P/TBV (Annual)0.70x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)175.86%

Cash Flow / Share (Quarterly)$-0.53

Price vs S&P 500 (YTD)101.15%

Net Profit Margin (TTM)-18.92%

EPS (TTM)$-1.11

10-Day Avg Trading Volume0.43M

EPS Excl Extra (TTM)$-1.11

EPS (Annual)$-0.11

ROI (Annual)-6.03%

Cash / Share (Quarterly)$0.75

ROA (Last FY)-4.28%

Revenue Growth TTM (YoY)1556.51%

EBITD / Share (TTM)$-0.90

ROE (5Y Avg)-45.18%

Operating Margin (TTM)-28.63%

Cash Flow / Share (Annual)$-1.20

P/B Ratio1.31x

P/B Ratio (Quarterly)1.53x

Net Income / Employee (Annual)$-122,800

EV / Revenue (TTM)2.59x

Net Interest Coverage (TTM)-90.50x

ROA (TTM)-39.93%

EPS Incl Extra (Annual)$-0.11

Current Ratio (Annual)5.97x

Quick Ratio (Quarterly)9.96x

3-Month Avg Trading Volume1.07M

52-Week Price Return291.72%

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$1.28

P/S Ratio (Annual)3.19x

Asset Turnover (Annual)0.49x

52-Week High$3.04

EPS Excl Extra (Annual)$-0.11

CapEx CAGR (5Y)-43.36%

26-Week Price Return0.95%

Quick Ratio (Annual)5.83x

13-Week Price Return-6.61%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)10.25x

Enterprise Value$297.04M

Asset Turnover (TTM)0.31x

Revenue / Employee (Annual)$1,399,500

Pretax Margin (Annual)-8.84%

Cash / Share (Annual)$1.34

3-Month Return Std Dev58.90%

Net Income / Employee (TTM)$-1,381,800

ROE (Last FY)-6.03%

Net Interest Coverage (Annual)-93.52x

EPS Basic Excl Extra (Annual)$-0.11

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-1.11

ROI (TTM)-53.23%

P/S Ratio (TTM)3.03x

Revenue / Share (Annual)$1.26

Tangible BV / Share (Annual)$1.43

Price vs S&P 500 (52W)273.41%

Year-to-Date Return113.11%

5-Day Price Return8.16%

EPS Normalized (Annual)$-0.11

ROA (5Y Avg)-25.36%

Net Profit Margin (Annual)-8.78%

Month-to-Date Return4.95%

Cash Flow / Share (TTM)$-1.98

EBITD / Share (Annual)$-0.05

Operating Margin (Annual)-15.82%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-44.78%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-1.11

P/TBV (Quarterly)1.76x

P/B Ratio (Annual)0.55x

Pretax Margin (TTM)-17.38%

Book Value / Share (Annual)$1.82

Price vs S&P 500 (13W)-9.40%

Beta1.64x

Revenue / Share (TTM)$0.00

ROE (TTM)-53.23%

52-Week Low$0.43

vGradeB

gGradeA

mGradeB

vgmGradeB

IPSC Earnings Surprise History

Q2 25-0.38est. -0.38

Q3 25-0.32est. -0.39

Q4 25-0.25est. -0.30

Q1 26-0.11est. -0.17

Q2 26-0.11est. -0.12

IPSC Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.00

Industry Peers — Biological Products(183)

Symbol	Value Score	Growth Score	Momentum Score	Price
IPSCCentury Therapeutics, Inc. Common Stock	B	A	B	$2.17
AMGNAmgen Inc	C	C	B	$442.24
GILDGilead Sciences Inc	C	B	B	$148.77
MRNAModerna, Inc. Common Stock	D	C	A	$158.83
ARGXargenx SE American Depositary Shares	D	A	B	$1019.49
RVMDRevolution Medicines, Inc. Common Stock	F	—	A	$211.38
BIIBBiogen Inc. Common Stock	C	D	B	$220.77
BNTXBioNTech SE American Depositary Share	C	C	B	$114.05
NBIXNeurocrine Biosciences Inc	C	B	C	$153.37
EXELExelixis Inc	C	B	B	$56.72
HALOHalozyme Therapeutics, Inc.	C	B	A	$109.32
TECHBio-Techne Corp.	D	C	B	$72.33
KRYSKrystal Biotech, Inc. Common Stock	D	B	B	$356.19
KYMRKymera Therapeutics, Inc. Common Stock	D	B	B	$126.64
RGENRepligen Corp	D	C	A	$181.69
APGEApogee Therapeutics, Inc. Common Stock	—	—	A	$134.85
TWSTTwist Bioscience Corporation Common Stock	D	B	A	$151.42
PCVXVaxcyte, Inc. Common Stock	—	—	B	$61.09
QGENQIAGEN N.V.	C	C	C	$43.65
IMVTImmunovant, Inc. Common Stock	—	—	B	$43.50
IBRXImmunityBio, Inc. Common Stock	F	A	C	$8.19
SRRKScholar Rock Holding Corporation Common Stock	F	—	B	$58.25
CGONCG Oncology, Inc. Common stock	F	A	A	$78.95
CRSPCRISPR Therapeutics AG	D	B	B	$60.90
RLAYRelay Therapeutics, Inc. Common Stock	F	D	A	$20.57
ADPTAdaptive Biotechnologies Corporation Common Stock	D	B	A	$26.25
DNLIDenali Therapeutics Inc. Common Stock	F	—	B	$24.93
IOVAIovance Biotherapeutics, Inc. Common Stock	C	B	A	$8.44
BEAMBeam Therapeutics Inc. Common Stock	C	B	B	$31.03
TARSTarsus Pharmaceuticals, Inc. Common Stock	D	A	B	$71.45
BCRXBioCryst Pharmaceuticals Inc	B	A	B	$9.83
KODKodiak Sciences Inc Common Stock	—	—	B	$39.46
COAGHemab Therapeutics Holdings, Inc. Common Stock	—	—	B	$49.65
MESOMesoblast Limited American Depositary Shares	D	B	C	$17.19
VCELVericel Corporation	D	B	C	$43.22
ADMAADMA Biologics, Inc.	C	C	C	$9.72
TSHATaysha Gene Therapies, Inc. Common Stock	F	B	B	$6.20
IMCRImmunocore Holdings plc American Depositary Shares	D	B	B	$37.40
RXRXRecursion Pharmaceuticals, Inc. Class A Common Stock	D	C	C	$3.56
VIRVir Biotechnology, Inc. Common Stock	B	B	B	$10.71
INBXInhibrx Biosciences, Inc. Common Stock	D	C	B	$122.72
ALVOAlvotech Ordinary Shares	C	D	B	$5.05
MAZEMaze Therapeutics, Inc. Common Stock	—	—	B	$30.42
NVAXNovavax Inc	B	D	C	$9.44
REPLReplimune Group, Inc.	—	—	A	$15.80
SLBTSL Science Holding Limited Ordinary Shares	—	—	F	$2.64
MGTXMeiraGTx Holdings plc Ordinary Shares	D	C	A	$14.92
VORVor Biopharma Inc. Common Stock	—	—	B	$24.01
CGEMCullinan Therapeutics, Inc. Common Stock	—	—	A	$22.95
IMTXImmatics N.V. Ordinary Shares	C	D	C	$9.24
ODTXOdyssey Therapeutics, Inc. Common Stock	—	C	A	$26.23

About Century Therapeutics, Inc. Common Stock

Century Therapeutics develops allogeneic cell therapies for cancer, autoimmune, and inflammatory diseases using CRISPR-engineered stem cells and proprietary immune-evasion technology. The company's platform overcomes key limitations of first-generation cell therapies by reducing immune rejection and simplifying manufacturing. This approach enables faster development cycles, improved scalability, and reduced supply chain risks.